Events
Amarantus Bioscience Holdings, Inc. announced that positive results from in vitro and animal studies on MANF in the treatment of Wolfram Syndrome were presented at the 79th Annual Scientific Sessions of the American Diabetes Association.
The Society for Clinical Research Sites announced that it is accepting submissions for two upcoming awards given at its annual Global Site Solutions Summit: the Site Patient Recruitment Innovation Award, and the Site Tank Award.
Todos Medical Ltd. announced that CEO Herman Weiss, MD, MBA, FACOG, provided a corporate update and roadmap at LD Micro International Annual Invitational in Los Angelos, California.
GENFIT announced the results of the voting by shareholders at the Ordinary Shareholders’ Meeting which took place on June 13, 2019, in Lille, France.
Clinical Ink is pleased to announce that Jonathan Andrus, chief business officer at Clinical Ink, has been invited to be a panelist in a public meeting hosted by the Duke-Margolis Center for Health Policy on July 17, 2019, in Washington, D.C. The workshop, convened under a cooperative agreement with the FDA, will discuss opportunities to improve the implementation of risk-based monitoring (RBM) in clinical investigations.
The International Biofilm Summit, addressing the main threat to food contamination, seizes the opportunity of its third edition on 23-24 October to take it to the next level.
As a sign of its international importance, the BIO Asia-Taiwan 2019 exhibition will feature 18 national pavilions, while the conference will feature speakers from 25 countries
Cipher Pharmaceuticals Inc., in accordance with Toronto Stock Exchange requirements, announced the voting results for the election of directors at its Annual and Special Meeting of Shareholders held on June 11, 2019 in Toronto, Ontario.
Neos Therapeutics, Inc. announced that Jerry McLaughlin, its Chief Executive Officer, will present a company overview at two upcoming conferences in June.
Pyrrolobenzodiazepine-based antibody drug conjugates demonstrate potential for the treatment of relapsed or refractory lymphomas as single agents and in combination therapies
PRESS RELEASES